AAV2 Capsid Mutations for Liver Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dependoparvovirus vectors, such as adeno-associated viruses (AAVs), face limitations in liver transduction efficiency, necessitating the development of improved capsid proteins to enhance delivery of payloads to cells, particularly in human subjects.
Innovation Solution
The development of variant dependoparvovirus capsid proteins, specifically AAV2 variants with mutations at defined positions, such as N449Q, T450S, P451G, S452G, T455A, T456A, S458D, and R459Q, which are used to create viral particles with increased liver transduction capabilities compared to wild-type AAV2 particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type AAV2 capsid proteins are used, then the viral particles can be produced, but the liver transduction efficiency is limited
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at defined positions (449-459) in the AAV2 capsid protein sequence. These mutations alter the physical-chemical properties of the capsid surface, enabling enhanced interaction with liver cell receptors and significantly improving liver transduction efficiency up to 250-fold compared to wild-type AAV2
Solution Approach 2:
The invention applies local quality by making targeted modifications only at specific residues (449-459) within the capsid protein rather than altering the entire structure. This localized approach preserves the overall capsid integrity and function while optimizing the specific region responsible for liver cell recognition and entry
2Reliability
If capsid protein mutations are introduced to enhance liver transduction, then transduction efficiency increases, but the capsid structure may be altered
Solution Approach 1:
The patent carefully selects amino acid substitutions that change local properties without disrupting global capsid stability. The mutations at positions 449-459 are strategically chosen to optimize liver targeting while maintaining the structural integrity required for viral assembly and function
Solution Approach 2:
By confining mutations to a specific region (residues 449-459) of the capsid protein, the invention preserves the stability and overall structure of the capsid while optimizing local interaction properties for enhanced liver transduction
Data Source
AI summary
The disclosure is directed in part to variant capsid polypeptides that can be used to deliver pay loads.